Talphera Inc

Talphera operates with a strong liquidity position, as evidenced by its cash and equivalents of $12.12 million, which represents 42.1% of its total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 5.97 suggests that the company has more than sufficient current assets to cover its current liabilities. Despite its strong liquidity, Talphera is currently unprofitable, with a net loss of $3.95 million and an operating loss of $2.99 million in the latest reporting period. The company's return on equity (ROE) is -24.21%, and its return on assets (ROA) is -13.74%, both significantly below the industry median for pharmaceutical firms. The EV/EBITDA ratio is negative at -11.52, reflecting the company's current unprofitability and lack of positive cash flow. Talphera's revenue is not disclosed in the latest financials, and no segment or geographic breakdown is available in the provided data. However, the absence of segment-specific data suggests that the company may be in an early stage of development or may not have disclosed such information in its latest filings. The company's growth trajectory is uncertain, as no revenue history is provided. Analysts have assigned a mean price target of $3.25, with a median of $3.25, suggesting a potential upside from the current market price of $0.8975. However, the lack of positive earnings and operating cash flow raises concerns about the company's ability to sustain growth in the near term. Talphera's risk profile is currently low in terms of liquidity and dilution, with no immediate filing-based flags detected. The company has not issued any new shares in the latest period, and its diluted share count is equal to its basic share count, indicating no dilution pressure at this time. However, the company's negative net income and operating cash flow could become a concern if it requires additional capital in the future. No recent events, such as earnings calls, regulatory filings, or major business developments, are disclosed in the provided data. The company's financials suggest it is in a development or early commercialization phase, with no significant capital expenditures reported in the latest period.